Clinical Trial Update: Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose [Phase 2]

View source ↗

Summary

Phase 2 immunogenicity and safety study of GlaxoSmithKline's GSK2202083A vaccine given as a booster; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Tetanus

Drugs mentioned

• GSK2202083A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tetanus, Diphtheria | Phase 2 | Status: COMPLETED | Results posted: 2017-04-11